DARA
BioSciences DARA announced today it has launched Soltamox®
(tamoxifen citrate) oral solution in the United States. Soltamox is
a new treatment option for breast cancer patients who are prescribed
tamoxifen therapy. DARA has exclusive U.S. rights to Soltamox from
Rosemont Pharmaceuticals, Ltd, UK.
Soltamox, liquid version of tamoxifen citrate (Photo: Business Wire)
Since its approval in 1977, tamoxifen has been used to treat millions of
women and men diagnosed with hormone-receptor-positive breast cancer.
Treatment with tamoxifen lowers the risk of breast cancer recurrence,
breast cancer in the opposite breast, and death from breast cancer.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in